Our CEO, Dr Tim Oldham discusses the significance of AdAlta becoming a clinical stage company, as well as the aims of the Phase I trial of AD-214, the importance of developing therapies for fibrotic diseases and the significant pharma interest in therapies for Idiopathic Pulmonary Fibrosis.
Watch the video here